Unusual cause of obstructive uropathy: a pelvic chondrosarcoma

Authors

  • Víctor Enrique Corona-Montes Secretaría de Salud, Hospital General de México, “Dr. Eduardo Liceaga”, Ciudad de México, México.
  • Gerardo Fernández-Noyola Secretaría de Salud, Hospital General, “Dr. Manuel Gea González”. Ciudad de México, México.
  • Freddy Chablé-Montero Hospital San Ángel Inn Universidad. Ciudad de México, México.
  • Alicia María Cervantes-Sánchez Hospital San Ángel Inn Universidad. Ciudad de México, México.
  • C. Cruz-Reyes Secretaría de Salud, Hospital General de México, “Dr. Eduardo Liceaga”, Ciudad de México, México.
  • Duval Alejandro Borja-Menéndez Secretaría de Salud, Hospital General de México, “Dr. Eduardo Liceaga”, Ciudad de México, México.
  • Jesús Emmanuel Rosas-Nava Secretaría de Salud, Hospital General de México, “Dr. Eduardo Liceaga”, Ciudad de México, México.
  • Juan Eduardo Sánchez-Núñez Secretaría de Salud, Hospital General de México, “Dr. Eduardo Liceaga”, Ciudad de México, México.

DOI:

https://doi.org/10.48193/revistamexicanadeurologa.v82i2.813

Keywords:

Obstructive uropathy, mesenchymal chondrosarcoma, soft tissue sarcoma

Abstract

We report the case of a 37-year-old male patient who presented renal failure secondary to a pelvic tumor. The diagnostic approach revealed a pubic-dependent tumor corresponding to a mesenchymal chondrosarcoma that conditioned obstructive uropathy as well as bladder and sigmoid compression. Mesenchymal chondrosarcomas are soft tissue dependent sarcomas with an extremely rare incidence, the clinical importance of our report is due to the fact that chondrosarcomas, must be considered in the differential diagnoses of obstructive uropathy due to their compressive effect on the urinary tract. We carry out a brief review of diagnostic approach, therapeutic options and prognosis of this pathology.

References

Lichtenstein L, Bernstein D. Unusual benign and malignant chondroid tumors of bone. A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer. 1959;12(6):1142–57. doi: https://doi.org/10.1002/1097-0142(195911/12)12:6<1142::AID-CNCR2820120610>3.0.CO;2-D

Lin O,, Zakowski MF. Cytology of Soft Tissue, Bone, and Skin. In: Comprehensive Cytopathology. 3rd ed. Elsevier; 2008. p. Philadelphia.

Ghafoor S, Hameed MR, Tap WD, Hwang S. Mesenchymal chondrosarcoma: imaging features and clinical findings. Skeletal Radiol. 2021;50(2):333–41. doi: https://doi.org/10.1007/s00256-020-03558-x

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2018;29:iv51–67. doi: https://doi.org/10.1093/annonc/mdy096

Wein AJ, M.D AWP, M.D LRK, Novick AC. Campbell-Walsh Urologia/ Campbell-Walsh Urology. 11th ed. Ed. Médica Panamericana; 2008. 808 p.

Xu J, Li D, Xie L, Tang S, Guo W. Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years. PLOS ONE. 2015 Apr 7;10(4):e0122216. doi: https://doi.org/10.1371/journal.pone.0122216

Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer. 2015;51(3):374–81. doi: https://doi.org/10.1016/j.ejca.2014.11.007

Tsavaris O, Economopoulou P, Kotsantis I, Reppas L, Avgerinou C, Spathas N, et al. Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature. Frontiers in Oncology. 2018;8. doi: https://doi.org/10.3389/fonc.2018.00045

Nakashima Y, Unni KK, Shives TC, Swee RG, Dahlin DC. Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer. 1986;57(12):2444–53. doi: https://doi.org/10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K

Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes, Chromosomes and Cancer. 2012;51(2):127–39. doi: https://doi.org/10.1002/gcc.20937

Shapeero LG, Vanel D, Couanet D, Contesso G, Ackerman LV. Extraskeletal mesenchymal chondrosarcoma. Radiology. 1993;186(3):819–26. doi: https://doi.org/10.1148/radiology.186.3.8430193

Mendenhall WM, Reith JD, Scarborough MT, Stechmiller BK, Mendenhall NP. Mesenchymal Chondrosarcoma. Int J Part Ther. 2016;3(2):300–4. doi: https://doi.org/10.14338/IJPT-16-00019.1

Tansir G, Rastogi S, Barwad A, Dhamija E. Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma. Clinical Sarcoma Research. 2020;10(1):16. doi: https://doi.org/10.1186/s13569-020-00138-4

Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16(4):406–16. doi: https://doi.org/10.1016/S1470-2045(15)70098-7

Araki N, Takahashi S, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. European Journal of Cancer. 2016;56:122–30. doi: https://doi.org/10.1016/j.ejca.2015.12.014

Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007;93(5):423–7.

Downloads

Published

2022-05-11

Issue

Vol. 82 No. 2 (2022): March-April

Section

Clinical cases

License

Copyright (c) 2022 Revista Mexicana de Urología

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.